U.S. markets close in 3 hours 51 minutes
  • S&P 500

    3,844.67
    +45.76 (+1.20%)
     
  • Dow 30

    31,142.65
    +212.13 (+0.69%)
     
  • Nasdaq

    13,431.37
    +234.19 (+1.77%)
     
  • Russell 2000

    2,161.17
    +10.03 (+0.47%)
     
  • Crude Oil

    53.37
    +0.39 (+0.74%)
     
  • Gold

    1,866.90
    +26.70 (+1.45%)
     
  • Silver

    25.77
    +0.45 (+1.80%)
     
  • EUR/USD

    1.2115
    -0.0018 (-0.15%)
     
  • 10-Yr Bond

    1.0970
    +0.0050 (+0.46%)
     
  • GBP/USD

    1.3660
    +0.0026 (+0.19%)
     
  • USD/JPY

    103.5600
    -0.3320 (-0.32%)
     
  • BTC-USD

    34,661.60
    +261.62 (+0.76%)
     
  • CMC Crypto 200

    686.29
    -14.32 (-2.04%)
     
  • FTSE 100

    6,740.39
    +27.44 (+0.41%)
     
  • Nikkei 225

    28,523.26
    -110.20 (-0.38%)
     

Eagle Pharmaceuticals, Inc.'s (NASDAQ:EGRX) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Simply Wall St
·3 min read

Most readers would already be aware that Eagle Pharmaceuticals' (NASDAQ:EGRX) stock increased significantly by 12% over the past three months. However, we wonder if the company's inconsistent financials would have any adverse impact on the current share price momentum. In this article, we decided to focus on Eagle Pharmaceuticals' ROE.

Return on equity or ROE is an important factor to be considered by a shareholder because it tells them how effectively their capital is being reinvested. Put another way, it reveals the company's success at turning shareholder investments into profits.

View our latest analysis for Eagle Pharmaceuticals

How Is ROE Calculated?

The formula for return on equity is:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for Eagle Pharmaceuticals is:

2.9% = US$4.9m ÷ US$173m (Based on the trailing twelve months to September 2020).

The 'return' is the income the business earned over the last year. That means that for every $1 worth of shareholders' equity, the company generated $0.03 in profit.

What Has ROE Got To Do With Earnings Growth?

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don’t share these attributes.

Eagle Pharmaceuticals' Earnings Growth And 2.9% ROE

It is quite clear that Eagle Pharmaceuticals' ROE is rather low. Even when compared to the industry average of 16%, the ROE figure is pretty disappointing. For this reason, Eagle Pharmaceuticals' five year net income decline of 8.1% is not surprising given its lower ROE. We believe that there also might be other aspects that are negatively influencing the company's earnings prospects. Such as - low earnings retention or poor allocation of capital.

However, when we compared Eagle Pharmaceuticals' growth with the industry we found that while the company's earnings have been shrinking, the industry has seen an earnings growth of 11% in the same period. This is quite worrisome.

past-earnings-growth
past-earnings-growth

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. It’s important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is Eagle Pharmaceuticals fairly valued compared to other companies? These 3 valuation measures might help you decide.

Is Eagle Pharmaceuticals Using Its Retained Earnings Effectively?

Conclusion

On the whole, we feel that the performance shown by Eagle Pharmaceuticals can be open to many interpretations. While the company does have a high rate of profit retention, its low rate of return is probably hampering its earnings growth. Having said that, looking at current analyst estimates, we found that the company's earnings growth rate is expected to see a huge improvement. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.